Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Pain
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Pain
    Preemptive Local Analgesia Reduces Pain and Narcotic Use After Vaginal Hysterectomy: Presented at AUGS - (DGDispatch)
    TopAbstracts in Pain 09/04/2008 - (DGNews)
    Duloxetine Effectively Reduces Concomitant Pain in Depressive Patients: Presented at ECNP - (DGDispatch)
    TopAbstracts in Pain 08/28/2008 - (DGNews)
    Gene Variants Influence Women's Response to Morphine After C-Section - (DGNews)

    News archive

     Recent webcasts/CME - Pain
      Acute Pain Management and Opioid Treatment: Community Pharmacist Perspectives
      Enhanced NSAID Delivery: Emerging Technologies
      Balanced Opioid Prescribing
      Persistent, Not Permanent: Alleviating Symptoms in Chronic Knee Pain
      Opioid Addiction: No Reason to Withhold Pain Management

      Webcasts/CME archive

       Recent cases - Pain
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
        Gluteal Pyomyositis as a Rare Cause of Sciatica in a Temperate Region: A Case Report
        A Rare Cause of Forearm Pain: Anterior Branch of the Medial Antebrachial Cutaneous Nerve Injury: A Case Report
        An Unusual Presentation of Complex Regional Pain Syndrome Type I
        Otitis Externa - What a Pain in the Neck!

        Cases archive
          




        my personal edition > pain > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Duloxetine Improves Functional Outcomes in Diabetic Neuropathic Pain: Presented at AAPM

        By Crystal Phend

        SAN DIEGO, C.A. -- March 1, 2006 -- Duloxetine treatment for diabetic peripheral neuropathic pain yields significant improvements in functional outcomes compared to placebo, according to a study presented here at the annual meeting of the American Academy of Pain Medicine. (AAPM).

        Duloxetine (Cymbalta) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) approved in the United States to treat depression and diabetic peripheral neuropathic pain.

        The researchers pooled results from three 12-week double blind, placebo-controlled studies of patients with diabetic peripheral neuropathic pain. A total of 1175 patients in the three studies were randomized to receive duloxetine 20 mg four times daily, 60 mg four times daily, 60 mg twice daily, or placebo.

        "We all know pain doesn't exist without some coexisting depression," said coauthor Jerry Hall, MD, Clinical Research Physician, Eli Lilly and Company, Indianapolis, Indiana, United States, in a presentation on February 23rd.

        However, to separate out the effects of duloxetine on pain, patients with depressive disorders were excluded from the studies. Only patients that completed treatment and received the 60 mg dose of duloxetine were included in the pooled analysis.

        Functional outcomes were measured by the interference portion of the Brief Pain Inventory, Short Form 36 (SF36), and the European Quality of Life Instrument 5D (EQ-5D).

        Both 60 mg duloxetine dosing groups had significantly better scores compared to placebo on the SF-36 subscales for general health, bodily pain, vitality, physical score, physical functioning, and role physical (function as an employee, parent, etc).

        Both dose groups were also significantly superior compared to placebo in the Brief Pain Inventory scales, which identifies how much the patient's pain interferes with daily life activities and sleep.

        Quality of life scores were also significantly higher for patients treated with either dose of duloxetine compared to placebo.

        "It works well," Dr. Hall said. However, he cautioned that the improvement could not be directly related to pain relief from duloxetine.

        This study was funded by Eli Lilly and Company.


        [Presentation title: Duloxetine in the Treatment of Diabetic Peripheral Neuropathic Pain: Evaluation of Functional Outcomes. Poster 108]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send